HOOMAN NOORCHASHM
Medical Practice in Penn Valley, PA
License number
Pennsylvania MT183538
Category
Medicine
Type
Graduate Medical Trainee
Address
Address
Penn Valley, PA 19072
Personal information
See more information about HOOMAN NOORCHASHM at radaris.comName
Address
Phone
Merion Station, PA
109 Chestnut Ave, Narberth, PA 19072
Professional information
Use Of B Lymphocyte Stimulator Protein Antagonists To Promote Transplantation Tolerance
US Patent:
2011001, Jan 20, 2011
Filed:
Feb 12, 2010
Appl. No.:
12/705551
Inventors:
Thi-Sau Migone - Gaithersburg MD, US
Hooman Noorchashm - Narberth PA, US
Michael Cancro - Media PA, US
Hooman Noorchashm - Narberth PA, US
Michael Cancro - Media PA, US
Assignee:
HUMAN GENOME SCIENCES, INC. - ROCKVILLE MD
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA - PHILADELPHIA PA
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA - PHILADELPHIA PA
International Classification:
A61K 39/395, A61K 38/16, A61K 38/13, A61P 37/06
US Classification:
4241331, 514 212, 4241731, 4241391, 514 205
Abstract:
The invention relates to methods of preventing, treating, ameliorating and otherwise inhibiting organ or transplant rejection in a patient by administering B Lymphocyte Stimulator antagonists. In addition, therapeutic treatment regimens are provided to promote transplant tolerance in a patient following the administration of B Lymphocyte Stimulatorantagonists.
Screening For Cd93 (C1Qrp)-Associated Polymorphism(S) In The Diagnosis, Prevention And Treatment Of Autoimmune Diseases
US Patent:
2011001, Jan 20, 2011
Filed:
Dec 19, 2007
Appl. No.:
12/520515
Inventors:
Hooman Noorchashm - Narberth PA, US
Ali Naji - North Wales PA, US
Ali Naji - North Wales PA, US
Assignee:
THE TRUSTEES OF THE UNIVESITY OF PENNSYLVANIA - Philidelphia PA
International Classification:
C12Q 1/68, C07H 21/04, C07H 21/00, C12N 15/63, C07K 14/705, C07K 16/28, G01N 33/566
US Classification:
435 6, 536 235, 536 231, 4353201, 530396, 5303879, 435 724
Abstract:
This invention is directed to a marker gene for autoimmune disease. Specifically, the invention is directed to the use of a polymorph of CD93 in methods and compositions for the detection, prognosis and therapy of Type I Diabetes and systemic lupus erythematosus (SLE).